ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AKTS / financials
ANRO (33) JBIO (31) CYRX (39) ALMS (18) ⌘ Pro Terminal →

Aktis Oncology Inc. (AKTS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$14.59 -8.41% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.34

Aktis Oncology Inc. (AKTS) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $886.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AKTS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AKTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Aktis Oncology Inc. (NASDAQ: AKTS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $14.59 (-8.41% 1D, market cap $886.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, AKTS ranks #438 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AKTS compare to ANRO and JBIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTS carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ANRO (Alto Neuroscience Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $886.9M) and JBIO (Jade Biosciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $894.2M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AKTS?
▼

Per AKTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002035832), Aktis Oncology Inc. generated $111.3M in revenue, $0 in net income, and $0 in free cash flow against $264.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $14.34 (-1.70%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 22.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (10)Whales (3)SEC (13)Macro (6)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
$36 Bull$13 Base$11 Bear
📬 FREE AKTS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AKTS)Realized 20D OHLCV Swing Band: ±11.6%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY AKTS SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 22.3% FCF Margin ($24.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
49
Grade D$16.64-3.4% Next Q
Q2 (-2Q)
46
Grade D$16.08+2.3% Next Q
Q3 (-1Q)
44
Grade D$16.45-11.3% Next Q
Current
41
Grade D-$14.59-7.2% Hist 90D α
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AKTS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AKTS currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.23) and Max Pain ($15.32) forces dealer call-delta covering toward $35.90.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AKTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AKTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How AKTS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$24.8M (22.3% FCF Margin)
Revenue$111.3MGross Profit $57.9M (52%)Cost of Sales $53.4MOp Profit $0 (0%)OpEx (R&D/SG&A) $57.9MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY25
Rev $111.3M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$111.3M52%0%$0$015%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AKTS)

  • ✓Walkthrough of AKTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AKTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.21%🛡️ HOLDING TREND SUPPORT
2026-11-03O $16.85H $16.85L $14.59C $14.59VOL 251.5K
RES: $21.70SUP: $13.54SMA50: $20.23SMA200: $20.98
$35.56$29.88$24.19$18.51$12.83RES $21.70SUP $13.54$14.592026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AKTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AKTS Butterfly Map → + Track AKTS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AKTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AKTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AKTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AKTS)

Health Care Rank #438 of 1015 ⚔️ ANRO vs AKTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AKTS vs. ANRO, JBIO, CYRX, ALMS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Aktis Oncology Inc. (AKTS) ranks #438 by composite RQD confidence (41/100, grade D-) and #373 by equity capitalization ($886.0M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. AKTS currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AKTS ACTIVE
Aktis Oncology Inc.
D- 41/100 — — — -8.41% $886.0M Benchmark Subject
ANRO
Alto Neuroscience Inc.
E 33/100 — — -35.0% -1.81% $886.9M /anro-vs-akts →
JBIO
Jade Biosciences Inc.
E 31/100 — — -35.0% -0.92% $894.2M /jbio-vs-akts →
CYRX
CryoPort Inc.
D- 39/100 11.8x 47.1% -11.5% -6.13% $875.7M /cyrx-vs-akts →
ALMS
Alumis Inc.
E 18/100 — — -35.0% -5.20% $871.1M /alms-vs-akts →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002035832 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aktis Oncology Inc. (AKTS) reported GAAP revenue of $111.3M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, AKTS closed FY2025 with $264.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $111.3M $0 — — $264.9M —

3. AKTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AKTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Aktis Oncology Inc. (NASDAQ: AKTS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $14.59 (-8.41% 1D, market cap $886.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, AKTS ranks #438 in composite RQD confidence.

How does AKTS compare to ANRO and JBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTS carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ANRO (Alto Neuroscience Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $886.9M) and JBIO (Jade Biosciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $894.2M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AKTS?

Per AKTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002035832), Aktis Oncology Inc. generated $111.3M in revenue, $0 in net income, and $0 in free cash flow against $264.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AKTS trading relative to its 50-day, 200-day, and 52-week technical levels?

AKTS last traded at $14.59 (-8.41% on volume of 898,192 shares), positioning the stock -27.88% below its 50-day simple moving average ($20.23) and -30.46% below its 200-day simple moving average ($20.98). Across its 52-week range of $14.72 to $34.19, AKTS sits at the 0.0% percentile with a 14-day RSI of 39.1 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($12.90 to $16.28).

Direct Sub-Reports: AKTS RQD Cockpit AKTS 12M Forecast AKTS Earnings & Move AKTS Dividends & DRIP AKTS Insiders & 13F AKTS Whale Options AKTS Profit Sankey AKTS News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

AKTS — Aktis Oncology Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Aktis Oncology Inc. (AKTS) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $14.59 (-8.41% 1D, market capitalization $886.0M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Aktis Oncology Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Revenue for FY 2025 is reported as — which is consistent with a company not yet generating reported product revenue in that period.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Aktis Oncology Inc. (AKTS) reported $111.3M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $264.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $14.72 – $34.19 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations for AKTS. A prospective investor should note that 2nd-order ripple analysis cannot be performed from this dataset. The one externally named relationship, Padcev, appears only in a headline and is not mapped in the graph. Watch items: whether any collaboration referenced in news materially changes revenue, and whether the company's zero reported revenue persists into later filings.

  • Key Question #1: Can AKTS sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $111.3M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AKTS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AKTS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aktis Oncology Inc. (AKTS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AKTS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AKTS Bull vs. Bear Conversation Board — What's Your Call at $14.59?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AKTS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AKTS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $20.87 (+31.0%)
📌 Pinned Debate

The forensic balance sheet pillar scores 13 of 20 on an Altman Z of 2.5, a Piotroski F of 6/9, and Debt/Equity of 0.5, and the company

Don't sleep on AKTS's setup in Health Care. The forensic balance sheet pillar scores 13 of 20 on an Altman Z of 2.5, a Piotroski F of 6/9, and Debt/Equity of 0.5, and the company holds $37.8M in cash.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (41/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 3/20 institutional whale-flow stock at $15.93 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $11.95 (-25.0%)
Spot @ $15.93

Zero reported revenue, zero margins, and 0% ROIC and FCF yield mean no earnings or cash generation is visible to anchor the $16.85 pric

Here is the bear case nobody on the bull side wants to address on AKTS: Zero reported revenue, zero margins, and 0% ROIC and FCF yield mean no earnings or cash generation is visible to anchor the $16.85 price.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%